Aldeyra Therapeutics, Inc.
ALDX
$1.51
-$0.03-1.95%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 42.23% | -62.14% | 21.38% | -30.46% | -45.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -42.47% | -65.99% | -59.78% | -50.42% | -43.53% |
| Operating Income | 42.47% | 65.99% | 59.78% | 50.42% | 43.53% |
| Income Before Tax | 44.20% | 65.23% | 59.13% | 49.13% | 42.03% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 44.20% | 65.23% | 59.13% | 49.13% | 42.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 44.20% | 65.23% | 59.13% | 49.13% | 42.03% |
| EBIT | 42.47% | 65.99% | 59.78% | 50.42% | 43.53% |
| EBITDA | 42.81% | 66.43% | 60.02% | 50.62% | 43.68% |
| EPS Basic | 44.44% | 65.50% | 59.52% | 49.63% | 42.63% |
| Normalized Basic EPS | 44.44% | 65.44% | 59.53% | 49.65% | 42.61% |
| EPS Diluted | 44.44% | 65.50% | 59.52% | 49.63% | 42.63% |
| Normalized Diluted EPS | 44.44% | 65.44% | 59.53% | 49.65% | 42.61% |
| Average Basic Shares Outstanding | 0.46% | 0.72% | 0.98% | 1.00% | 1.06% |
| Average Diluted Shares Outstanding | 0.46% | 0.72% | 0.98% | 1.00% | 1.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |